コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 tion and VEGF synthesis in a murine model of proliferative retinopathy.
2 r findings using human and mouse retina with proliferative retinopathy.
3 bfields of the deep plexus with sickle SC or proliferative retinopathy.
4 ferable retinopathy, 97.9% (94.9%-99.1%) for proliferative retinopathy.
5 d females with VKH presented with unilateral proliferative retinopathy.
6 but may be more extensive with sickle SC or proliferative retinopathy.
7 coupling in a mouse model of oxygen-induced proliferative retinopathy.
8 declined for treatment of macular edema and proliferative retinopathy.
9 arization is a leading cause of blindness in proliferative retinopathy.
10 ially expressed sncRNAs in a murine model of proliferative retinopathy.
11 development of nephropathy, neuropathy, and proliferative retinopathy.
12 sed or considered at risk for progression to proliferative retinopathy.
13 utic target to inhibit neovascularization in proliferative retinopathy.
14 uced retinopathy (OIR), a postnatal model of proliferative retinopathy.
15 g in pathological retinal vascular growth in proliferative retinopathy.
16 arization in a mouse model of oxygen-induced proliferative retinopathy.
17 ss retinal neovascularization and to prevent proliferative retinopathy.
18 ful pharmaceutical intervention for treating proliferative retinopathy.
19 e data suggest that STAT3 may have a role in proliferative retinopathy.
20 may be an ideal target for the prevention of proliferative retinopathy.
21 ha-defensins were studied in hypoxia-induced proliferative retinopathy.
22 reatment with plasma of patients affected by proliferative retinopathy.
23 n to prevent retinal detachment in models of proliferative retinopathy.
24 were preferentially transduced in eyes with proliferative retinopathy.
25 initiation of the angiogenesis that leads to proliferative retinopathy.
26 arization in a mouse model of oxygen-induced proliferative retinopathy.
27 tor (VEGF) has transformed therapy for these proliferative retinopathies.
28 chments similar to those seen in humans with proliferative retinopathies.
29 an alternative approach in the management of proliferative retinopathies.
30 oxygen-induced retinopathy modeling ischemic proliferative retinopathies.
31 ation exists regarding the role of ADAM10 in proliferative retinopathies.
32 e leads to vascular complications in various proliferative retinopathies.
33 is crucial for pathological angiogenesis in proliferative retinopathies.
34 icance as a potential therapeutic target for proliferative retinopathies.
35 tions of ischemia-reperfusion encountered in proliferative retinopathies.
36 ic compounds for prevention and treatment of proliferative retinopathies.
37 s and regeneration and glia proliferation in proliferative retinopathies.
38 neovascularization is a crucial component of proliferative retinopathies.
39 a potential clinical use of this compound in proliferative retinopathies.
40 pathological conditions, such as cancer and proliferative retinopathies.
41 tide may be a promising future treatment for proliferative retinopathies.
42 vide a clinically efficient strategy against proliferative retinopathies.
43 peutic role for 16K hPRL in the treatment of proliferative retinopathies.
44 K2 inhibitors may be useful for treatment of proliferative retinopathies.
45 tant therapeutic target in the management of proliferative retinopathies.
46 PDGF) is an important stimulatory factor for proliferative retinopathies.
47 c inflammatory response in arthritis and the proliferative retinopathies.
48 the possibility that PGs may play a role in proliferative retinopathies.
49 intravitreous injections in mouse eyes with proliferative retinopathies.
50 en implicated in vascular development and in proliferative retinopathies.
51 pharmacologic therapies for the treatment of proliferative retinopathies.
52 investigate new treatments for patients with proliferative retinopathies.
53 the exaggerated wound repair that occurs in proliferative retinopathies.
54 7 [0.07-1.00], p = 0.05), and progression to proliferative retinopathy (0.18 [0.04-0.82], p = 0.03).
55 a lower HR of cataract surgery in eyes with proliferative retinopathy (0.903; 95% CI, 0.725-1.124),
56 nonproliferative retinopathy was 66% (75%); proliferative retinopathy, 24% (32%); maculopathy, 56% (
57 role for VEGF expression in ischemia-induced proliferative retinopathies and a potential therapeutic
58 as a therapeutic target in the treatment of proliferative retinopathies and other diseases dependent
59 ufficiency and retinal ischemia precede many proliferative retinopathies and stimulate secretion of v
61 sm, rs161740, with the combined phenotype of proliferative retinopathy and end-stage renal disease in
63 demonstrate that SDF-1 plays a major role in proliferative retinopathy and may be an ideal target for
64 ips between this factor and the incidence of proliferative retinopathy and of macular edema, 2 import
65 otein to be associated with the incidence of proliferative retinopathy and other complications of typ
67 lowest frequency of the active phase of the proliferative retinopathy and retinal macular edema, cha
68 VEGF is involved pathologically in cancer, proliferative retinopathy and rheumatoid arthritis, and
69 retinal space of wild-type mice or mice with proliferative retinopathies, and quantitative comparison
70 01) more likely to develop microalbuminuria, proliferative retinopathy, and distal symmetrical polyne
71 c control and the onset of microalbuminuria, proliferative retinopathy, and DSP observed in the Diabe
72 g incidences in Europe of overt nephropathy, proliferative retinopathy, and mortality in type 1 diabe
76 is a critical component of diseases such as proliferative retinopathies, cancer and rheumatoid arthr
79 to 0.65; P = 0.59); and laser treatment for proliferative retinopathy elasticity, 0.05 (95% CI, -0.2
80 from eyes of patients with diabetes without proliferative retinopathy, eyes of patients without diab
81 a direct link between ATF4 and the degree of proliferative retinopathy has not been demonstrated to d
83 )-A and PDGF-B is increased in patients with proliferative retinopathies in which traction retinal de
86 ors of diabetic nephropathy, neuropathy, and proliferative retinopathy in a young population-based Da
87 a may have helped prevent complications from proliferative retinopathy in eyes clinically observed to
88 ect out individual contributions, a model of proliferative retinopathy in mice with attenuated ephrin
89 ed, as is a significantly prolonged phase of proliferative retinopathy in PWG pups (20 days) compared
90 vessels commonly causes vision impairment in proliferative retinopathies, including retinopathy of pr
91 t the levels of SDF-1 found in patients with proliferative retinopathy induce retinopathy in our muri
93 angiogenesis in the pathological setting of proliferative retinopathy is a major cause of blindness
95 nificantly greater in mice with two types of proliferative retinopathy (ischemic retinopathy or trans
96 ither moderate-to-severe nonproliferative or proliferative retinopathy occurred on chromosomes 5 (2.5
97 n; (4) diabetic vitrectomy; (5) treatment of proliferative retinopathy of prematurity and (6) treatme
98 nnual dilated retinal examinations to detect proliferative retinopathy or clinically significant macu
99 was defined in FIELD as laser treatment for proliferative retinopathy or macular edema or increase b
100 lation therapy or vitrectomy, development of proliferative retinopathy, or progression of diabetic re
101 omplication; OR, 1.17; 95% CI, 1.13-1.21 for proliferative retinopathy; OR, 2.35; 95% CI, 2.18-2.54 f
102 roliferative retinopathy (NPDR), and 38 with proliferative retinopathy (PDR) were imaged using spectr
104 thy, nonproliferative retinopathy (NPR), and proliferative retinopathy (PR), determined as proportion
105 en precedes cerebral infarcts or hemorrhage, proliferative retinopathy prior to loss of eyesight, pul
107 oligodeoxynucleotides prior to the onset of proliferative retinopathy reduced new blood vessel growt
109 , or proliferative), 99.6% (97.0%-99.9%) for proliferative retinopathy; Retmarker 73.0% (72.0 %-74.0%
110 clining, others (CAD, overt nephropathy, and proliferative retinopathy) show less favorable changes b
112 ovide a good strategy for acute treatment of proliferative retinopathies, such as diabetic retinopath
113 actor (PDGF) has been implicated in vascular proliferative retinopathies, such as diabetic retinopath
115 een the cornerstone of studies investigating proliferative retinopathies, there is currently no harmo
116 mity complication, end-stage kidney disease, proliferative retinopathy, treatment for retinopathy, an
117 he eyes that developed SVLV before high-risk proliferative retinopathy was observed, baseline risk fa
120 ession in DR with diabetic macular edema and proliferative retinopathy, when compared to nondiabetic
122 cell hemoglobinopathy (SCH) can demonstrate proliferative retinopathy with vision loss, but lack of
123 he potential increase in the HR for incident proliferative retinopathy, with an increase in oxidized